Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Non-Current Deffered Revenue (2016 - 2024)

Historic Non-Current Deffered Revenue for Seres Therapeutics (MCRB) over the last 9 years, with Q2 2024 value amounting to $95.4 million.

  • Seres Therapeutics' Non-Current Deffered Revenue rose 46.04% to $95.4 million in Q2 2024 from the same period last year, while for Jun 2024 it was $95.4 million, marking a year-over-year increase of 46.04%. This contributed to the annual value of $95.4 million for FY2023, which is 317.43% up from last year.
  • As of Q2 2024, Seres Therapeutics' Non-Current Deffered Revenue stood at $95.4 million, which was up 46.04% from $95.4 million recorded in Q1 2024.
  • Seres Therapeutics' Non-Current Deffered Revenue's 5-year high stood at $95.4 million during Q4 2023, with a 5-year trough of $78.4 million in Q2 2021.
  • For the 5-year period, Seres Therapeutics' Non-Current Deffered Revenue averaged around $88.8 million, with its median value being $89.7 million (2021).
  • In the last 5 years, Seres Therapeutics' Non-Current Deffered Revenue plummeted by 2440.54% in 2020 and then soared by 1581.77% in 2023.
  • Over the past 5 years, Seres Therapeutics' Non-Current Deffered Revenue (Quarter) stood at $85.6 million in 2020, then increased by 1.67% to $87.0 million in 2021, then rose by 6.24% to $92.4 million in 2022, then grew by 3.17% to $95.4 million in 2023, then changed by 0.0% to $95.4 million in 2024.
  • Its last three reported values are $95.4 million in Q2 2024, $95.4 million for Q1 2024, and $95.4 million during Q4 2023.